Extracted Insight
Stock Market Impact: Shares of Spruce Biosciences Inc (NASDAQ:SPRB) climbed 3.2% in after‑hours trading on Monday following the release of long‑term clinical data for its MPS IIIB enzyme replacement therapy.
Listed Companies and Sectors: The data pertain to Spruce Biosciences, a biotech company operating in the Pharma / Healthcare sector. The presentation at the 18th International MPS & Related Lysosomal Diseases Symposium detailed results for tralesinidase alfa (TA‑ERT) in Sanfilippo Syndrome Type B (MPS IIIB).
Clinical Data Details: In a cohort of 22 patients with up to six years of follow‑up, TA‑ERT rapidly and durably normalized cerebrospinal fluid heparan sulfate non‑reducing end (CSF HS‑NRE) levels. The therapy also stabilized cognitive function measured by Bayley‑III Cognitive Raw Score, receptive and expressive communication, fine and gross motor skills, cortical gray matter volume, and liver and spleen volume, compared with declines observed in untreated natural‑history controls.
Investment Flows: Jones Trading analyst Catherine Novack initiated coverage with a buy rating and a price target of $135. She highlighted a potential approval of TA‑ERT in mid‑2027 and an estimated $180 million cash inflow from a priority review voucher upon approval.
Financial Position: Spruce Biosciences reported pro‑forma cash of $107.3 million as of 30 April 2026, providing runway into the second half of 2027, excluding any product revenue or voucher proceeds.